(Q33332473)

English

Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

25 July 2017

Treatment of patients with recurrent and primary refractory acute myelogenous leukemia using mitoxantrone and intermediate-dose cytarabine: a pharmacologically based regimen (English)

1 reference

Europe PubMed Central

25 July 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Sternberg DW

1

1 reference

Europe PubMed Central

25 July 2017

Aird W

2

1 reference

Europe PubMed Central

25 July 2017

Neuberg D

3

1 reference

Europe PubMed Central

25 July 2017

Thompson L

4

1 reference

Europe PubMed Central

25 July 2017

MacNeill K

5

1 reference

Europe PubMed Central

25 July 2017

Amrein P

6

1 reference

Europe PubMed Central

25 July 2017

Shulman LN

7

1 reference

Europe PubMed Central

25 July 2017

language of work or name

0 references

publication date

1 May 2000

1 reference

Europe PubMed Central

25 July 2017

1 reference

Europe PubMed Central

25 July 2017

88

1 reference

Europe PubMed Central

25 July 2017

9

1 reference

Europe PubMed Central

25 July 2017

2037-2041

1 reference

Europe PubMed Central

25 July 2017

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2820000501%2988%3A9%3C2037%3A%3AAID-CNCR8%3E3.0.CO%3B2-K

21 January 2018

Treatment of relapsed or refractory AML with intermediate-dose arabinosylcytosine (ara-C): confirmation of the importance of ara-C triphosphate formation in mediating response to ara-C.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2820000501%2988%3A9%3C2037%3A%3AAID-CNCR8%3E3.0.CO%3B2-K

21 January 2018

Mitoxantrone-induced DNA damage in leukemia cells is enhanced by treatment with high-dose arabinosylcytosine

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2820000501%2988%3A9%3C2037%3A%3AAID-CNCR8%3E3.0.CO%3B2-K

21 January 2018

Idarubicin and intermediate dose ARA-C followed by consolidation chemotherapy or bone marrow transplantation in relapsed or refractory acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2820000501%2988%3A9%3C2037%3A%3AAID-CNCR8%3E3.0.CO%3B2-K

21 January 2018

Acute myeloid leukemia in patients more than 50 years of age: special considerations in diagnosis, treatment, and prognosis

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2820000501%2988%3A9%3C2037%3A%3AAID-CNCR8%3E3.0.CO%3B2-K

21 January 2018

Granulocyte-macrophage colony-stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. Cancer and Leukemia Group B.

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2820000501%2988%3A9%3C2037%3A%3AAID-CNCR8%3E3.0.CO%3B2-K

21 January 2018

A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2820000501%2988%3A9%3C2037%3A%3AAID-CNCR8%3E3.0.CO%3B2-K

21 January 2018

FLAG (fludarabine, cytosine arabinoside, G-CSF) for refractory and relapsed acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2820000501%2988%3A9%3C2037%3A%3AAID-CNCR8%3E3.0.CO%3B2-K

21 January 2018

Improved survival for patients with acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2820000501%2988%3A9%3C2037%3A%3AAID-CNCR8%3E3.0.CO%3B2-K

21 January 2018

The management of recurrent acute myelogenous leukaemia at a single centre over a fifteen-year period

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2820000501%2988%3A9%3C2037%3A%3AAID-CNCR8%3E3.0.CO%3B2-K

21 January 2018

Probability of long-term disease-free survival for acute myeloid leukemia patients after first relapse: A single-centre experience

1 reference

https://api.crossref.org/works/10.1002%2F%28SICI%291097-0142%2820000501%2988%3A9%3C2037%3A%3AAID-CNCR8%3E3.0.CO%3B2-K

21 January 2018

Identifiers

10.1002/(SICI)1097-0142(20000501)88:9<2037::AID-CNCR8>3.0.CO;2-K

1 reference

Europe PubMed Central

25 July 2017

1 reference

Europe PubMed Central

25 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33332473&oldid=1513625762"